Zhijuan Miao1, Xin Tang1, Marianne Schultzberg2, Yuwu Zhao1, Xiuzhe Wang1. 1. Department of Neurology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. 2. Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, Stockholm, Sweden.
Abstract
BACKGROUND: Diabetes mellitus (DM) aggravates symptoms and prognosis of acute ischemic stroke (AIS), and inflammation plays an important role therein. Resolvin D2 (RvD2) is one of the specialized pro-resolving mediators (SPMs), while leukotriene B4 (LTB4) is a classic proinflammatory mediator. The ratio of RvD2 to LTB4 is an index of pro-resolving/proinflammatory balance. We aim to explore the role of RvD2/LTB4 ratio in ischemic stroke complicated with DM. METHODS: The plasma levels of RvD2 and LTB4 were analyzed by enzyme immunoassay in stroke patients with DM (DM + AIS group) or without DM (nonDM+AIS group). Patients were followed up at 90 days after stroke onset, and modified Rankin Score (mRS) was assessed. The association of RvD2/LTB4 ratio with stroke severity and prognosis was also analyzed. RESULTS: The plasma levels of RvD2 were positively correlated to LTB4. The RvD2/LTB4 ratio in DM + AIS group was lower than that in the nonDM+AIS group. No correlation was found between the RvD2/LTB4 ratio and infarct size or NIHSS score. The RvD2/LTB4 ratio at baseline was significantly lower in the poor prognosis group (mRS ≥ 3) than that in the good prognosis group (mRS ≤ 2). CONCLUSIONS: Our study indicated that the balance between pro-resolving and proinflammatory mediators was impaired by diabetes in ischemic stroke. The RvD2/LTB4 ratio may serve as a biomarker of prognosis for ischemic stroke.
BACKGROUND: Diabetes mellitus (DM) aggravates symptoms and prognosis of acute ischemic stroke (AIS), and inflammation plays an important role therein. Resolvin D2 (RvD2) is one of the specialized pro-resolving mediators (SPMs), while leukotriene B4 (LTB4) is a classic proinflammatory mediator. The ratio of RvD2 to LTB4 is an index of pro-resolving/proinflammatory balance. We aim to explore the role of RvD2/LTB4 ratio in ischemic stroke complicated with DM. METHODS: The plasma levels of RvD2 and LTB4 were analyzed by enzyme immunoassay in stroke patients with DM (DM + AIS group) or without DM (nonDM+AIS group). Patients were followed up at 90 days after stroke onset, and modified Rankin Score (mRS) was assessed. The association of RvD2/LTB4 ratio with stroke severity and prognosis was also analyzed. RESULTS: The plasma levels of RvD2 were positively correlated to LTB4. The RvD2/LTB4 ratio in DM + AIS group was lower than that in the nonDM+AIS group. No correlation was found between the RvD2/LTB4 ratio and infarct size or NIHSS score. The RvD2/LTB4 ratio at baseline was significantly lower in the poor prognosis group (mRS ≥ 3) than that in the good prognosis group (mRS ≤ 2). CONCLUSIONS: Our study indicated that the balance between pro-resolving and proinflammatory mediators was impaired by diabetes in ischemic stroke. The RvD2/LTB4 ratio may serve as a biomarker of prognosis for ischemic stroke.
Authors: Ho Pan Sham; Katherine H Walker; Raja-Elie E Abdulnour; Nandini Krishnamoorthy; David N Douda; Paul C Norris; Ioanna Barkas; Sarah Benito-Figueroa; Jennifer K Colby; Charles N Serhan; Bruce D Levy Journal: J Immunol Date: 2018-03-09 Impact factor: 5.422
Authors: Song Hong; Haibin Tian; Yan Lu; James Monroe Laborde; Filipe A Muhale; Quansheng Wang; Bhagwat V Alapure; Charles N Serhan; Nicolas G Bazan Journal: Am J Physiol Cell Physiol Date: 2014-10-01 Impact factor: 4.249
Authors: J R Sims; L Rezai Gharai; P W Schaefer; M Vangel; E S Rosenthal; M H Lev; L H Schwamm Journal: Neurology Date: 2009-06-16 Impact factor: 9.910
Authors: Adviye Ergul; Mostafa M Elgebaly; Mary-Louise Middlemore; Weiguo Li; Hazem Elewa; Jeffrey A Switzer; Christiana Hall; Anna Kozak; Susan C Fagan Journal: BMC Neurol Date: 2007-10-15 Impact factor: 2.474